This document discusses the importance of incorporating safety considerations into drug design from an early stage. It notes that safety issues related to the primary drug target remain a major reason for drug project failure and delay. Considering the target's normal physiological role allows researchers to anticipate and plan for potential toxicities. Early studies, such as in silico modeling, in vitro screening assays, and in vivo validations in animal models, can help identify potential safety hazards to hopefully design them out of drug candidates. Understanding toxicity risks in the context of the intended patient population can help assess the risk-benefit of a given drug target or compound series. Incorporating safety assessments from the beginning of the drug design process can lead to better informed decisions and improved chances of